Pathological Complete Response Likely Not a Reliable Survival Surrogate in Early Breast Cancer
A new meta-analysis suggests that pathological complete response should not be used as a surrogate endpoint in randomized trials of neoadjuvant therapies for early breast cancer.
Reuters Health Information
source https://www.medscape.com/viewarticle/966719?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/966719?src=rss
Comments
Post a Comment